LYEL LYELL IMMUNOPHARMA INC
FollowStock (common), issuer CIK 1806952
Filings received so far for Q3 2026: 5 13F filers report a position in LYEL shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.
13D and 13G filers
No 13D or 13G on this security in the data. Structured 13D/G data starts 2024-12-18.
Insider trades
| Owner | Date | Shares | Price | Filing |
|---|---|---|---|---|
| Aguirre Jarrad Mattieuofficer (Chief Medical Officer) | 2026-10-12 | -422 S | $8.63 | Form 4 |
13F holders, Q3 2026
Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.
| Holder | Shares | Value | % of portfolio | Change | Source |
|---|---|---|---|---|---|
| GAMMA Investing LLC | 353 | $3.46K | <0.01% | +318 | 13F-HRTimeline |
| Farther Finance Advisors, LLC | 144 | $1.41K | <0.01% | new | 13F-HRTimeline |
| Essential Partners LLC | 69 | $676 | <0.01% | new | 13F-HRTimeline |
| True Wealth Design, LLC | 45 | $441 | <0.01% | new | 13F-HRTimeline |
| Fortitude Family Office, LLC | 7 | $69 | <0.01% | new | 13F-HRTimeline |
Events
Aguirre Jarrad Mattieu sold 422 LYEL shares on 2026-10-12, Form 4 filed 2026-10-13. 0002150331-26-000003
Accepted , ingested